Drug Profile
ADV P8
Alternative Names: ADV-P8Latest Information Update: 20 Apr 2012
Price :
$50
*
At a glance
- Originator AdvanCell
- Developer Advancell
- Class Antidepressants
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Major depressive disorder
Most Recent Events
- 20 Apr 2012 No development reported - Phase-II for Major depressive disorder in Spain (unspecified route)
- 12 Jan 2009 Phase-II clinical trials in Depression in Spain (unspecified route)